『Eagle's Eye View: Your Weekly CV Update From ACC.org』のカバーアート

Eagle's Eye View: Your Weekly CV Update From ACC.org

Eagle's Eye View: Your Weekly CV Update From ACC.org

著者： American College of Cardiology
無料で聴く

The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.American College of Cardiology Foundation. All rights reserved. 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Genotype and Hypertrophic Cardiomyopathy; PARTNER 2A & TAVR 10 Years Later; Clopidogrel vs. Aspirin after PCI; LDL & Risk Assessment of ASCVD

    Genotype and Hypertrophic Cardiomyopathy; PARTNER 2A & TAVR 10 Years Later; Clopidogrel vs. Aspirin after PCI; LDL & Risk Assessment of ASCVD
    2026/07/01

    In this week's View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). He then examines the ten-year follow-up of the PARTNER 2A trial and compares the transcatheter aortic valve replacement (TAVR) outcomes to results from the Partner 2 SAPIEN XT and SAPIEN 3 studies. He follows this with a report on how clopidogrel may offer a long-term edge over aspirin after percutaneous coronary intervention (PCI). Finally, Dr. Eagle summarizes HELIUS cohort findings demonstrating that LDL-C, Lp(a), and hsCRP provide complementary, independent insights for identifying long-term atherosclerotic cardiovascular disease (ASCVD) risk across diverse ethnic populations.

    Subscribe to Eagle's Eye View  

    続きを読む 一部表示
    8 分
  • Guideline-Directed Medical Therapy & Atrial Fibrillation; Anti-Platelet Therapy & ASCVD; DOACs & Prevention of Thrombotic Events; Sugar-Sweetened Beverages and Fruit Juice & Hypertension

    Guideline-Directed Medical Therapy & Atrial Fibrillation; Anti-Platelet Therapy & ASCVD; DOACs & Prevention of Thrombotic Events; Sugar-Sweetened Beverages and Fruit Juice & Hypertension
    2026/07/08
    In this week's View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF). He follows this with commentary on two important recently released ACC scientific statements: one on anti-platelet therapy for atherosclerotic cardiovascular disease (ASCVD), and the other examining the use of direct oral anticoagulants (DOACs) for primary and secondary prevention of thrombotic events. Finally, Dr. Eagle summarizes a recent longitudinal study on sugar-sweetened beverages and fruit juice and their potential relationship to the development of hypertension later in a young person's life. Subscribe to Eagle's Eye View  
    続きを読む 一部表示
    9 分
  • Mechanical Leaflet Splitting and TAVR; Ambient Temperature & Marathons; AFib, PVI with PA & IRF; the SHaRE Registry as a Predictor of MACE

    Mechanical Leaflet Splitting and TAVR; Ambient Temperature & Marathons; AFib, PVI with PA & IRF; the SHaRE Registry as a Predictor of MACE
    2026/07/15

    In this week's View, Dr. Eagle looks at the feasibility of mechanical leaflet splitting in high-risk patients undergoing valve-in-valve TAVR. He follows this with an examination of lower ambient temperature and it association with greater SCA risk at marathon races, then offers a commentary on two studies that provide new insights on the durability of pulmonary vein isolation (PVI) with pulsed field ablation (PA) vs radiofrequency ablation IRF) in patients with persistent atrial fibrillation (AFib). Finally, Dr. Eagle discusses the SHaRe Registry and its use in predicting major adverse cardiovascular events MACE for patients with mild hypertrophic cardiomyopathy (HCM).

    Subscribe to Eagle's Eye View

    続きを読む 一部表示
    10 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません